ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more

7-11 Boulevard Haussmann, Paris, 75009, France

Biotechnology

Healthcare

Market Cap

9.971B

52 Wk Range

$5.59 - $148.83

Previous Close

$122.47

Open

$125.11

Volume

1,179,004

Day Range

$119.79 - $125.72

Enterprise Value

9.037B

Cash

530.4M

Avg Qtr Burn

-23.23M

Insider Ownership

0.00%

Institutional Own.

78.94%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Obefazimod Details Moderately to Severely Active Ulcerative Colitis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obefazimod Details Crohn’s Disease	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.